Phase 2 study of the IDO/PD-L1-targeted immune-modulatory vaccine, IO102-IO103, plus pembrolizumab as first-line treatment for metastatic non–small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), or urothelial bladder cancer (UBC).

Jonathan W. Riess, Ezra E.W. Cohen, Devraj Srinivasan et al.|Journal of Clinical Oncology|2022

Cited by 3